CGTLive’s Weekly Rewind – October 6, 2023

News
Article

Review top news and interview highlights from the week ending October 6, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. News and Expert Insights in Rare Cancer Cell Therapy for Rare Cancer Day

In observance of Rare Cancer Day, held annually on September 30, catch up on the past few months’ news and expert insights related to cell therapies in development for these indications.

2. Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for Sarcomas

The professor of medicine and pediatrics at Washington University in St. Louis discussed future challenges and exciting research in the sarcoma field.

3. Capricor Aligns With FDA on DMD Cell Therapy CAP-1002's Trial in Type-B Meeting

The company stated that based on the meeting, the trial’s primary end points will remain the same.

4. David Boyer, MD, on Promising Efficacy of Suprachoroidal Gene Therapy in nAMD

The senior partner at Retina Vitreous Associates Medical Group discussed efficacy and safety data from the phase 2 AAVIATE trial.

5. Rocket’s LAD-I Gene Therapy BLA Accepted for Priority Review

The therapy has a PDUFA date of March 31, 2024.

Related Videos
Mitchel Horwitz, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Paul Harmatz, MD
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
Aimee C. Talleur, MD, a physician at St. Jude Children’s Research Hospital
Related Content
© 2024 MJH Life Sciences

All rights reserved.